Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Multi-country retrospective analysis
Study drug and medical condition

Name of medicine

INTUNIV

Study drug International non-proprietary name (INN) or common name

GUANFACINE HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) code

(A) ALIMENTARY TRACT AND METABOLISM
ALIMENTARY TRACT AND METABOLISM
(C02AC02) guanfacine
guanfacine

Medical condition to be studied

Attention deficit hyperactivity disorder
Population studied

Short description of the study population

The study population included patients with attention deficit hyperactivity disorder (ADHD) who have been prescribed Intuniv® identified from the electronic medical record databases and national registries.

Age groups

Infants and toddlers (28 days – 23 months)
Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Patients with attention deficit/hyperactivity disorder

Estimated number of subjects

5000
Study design details

Main study objective

Overall: Drug utilization study for the next 5 years with Intuniv® with annual data in European countries. Study objectives: 1.characterize patients, focussing on indications other than ADHD, children <6 years, adults 2. describe prescribing patterns of Intuniv® among physicians 3. assess compliance with indication, visits and measurements needed during the first year of treatment</6></6>

Data analysis plan

The analysis will be done descriptively as specified in the statistical analysis plan.
Documents
Study results
English (2.94 MB - PDF)View document